ENGN enGene Bio: רווח למניה בשנים עשר החודשים האחרונים

The current rolling earnings per share level allows for an assessment of the potential of enGene Holdings Inc. (ENGN), which develops non-viral DNA delivery methods for mucosal therapy. Supply chain reliability is ensured by strict temperature control in logistics. Financial stability is based on the calculated expenditure of liquidity for current research. The value of -2.10 marks a new level, helping traders filter out market noise and identify yield dynamics in a timely manner.
פילוחים אנליטיים ודוחות נתונים של חברת enGene Bio (ENGN)

This indicator measures the rolling total of net income allocated per share over the last twelve months, allowing for an assessment of real value generation efficiency without accounting for capital dilution. Analyzing the 12-month rolling income per share is critical for evaluating the capitalization of enGene Holdings Inc. (ENGN), where profit depends directly on the success of clinical validation for cancer therapy and patent protection.